

Revision date: 05-Apr-2007

Version: 2.1

Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: CP-675,206 IV Solution, 5mg/mL

Trade Name:Not establishedChemical Family:Not determinedIntended Use:Pharmaceutical active used as Cancer immunotherapeutic agent

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
CP-675,206	Proprietary	Not listed	0.5

Ingredient	CAS Number	EU EINECS List	%
Polysorbate 80	9005-65-6	Not listed	*
Sodium Acetate	127-09-3	204-823-8	*
Water	7732-18-5	231-791-2	*
SODIUM CHLORIDE	7647-14-5	231-598-3	*
ACETIC ACID	64-19-7	200-580-7	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Signal Word:	clear liquid WARNING
Statement of Hazard: Additional Hazard Information:	May cause gastrointestinal system, liver, and blood effects.
Short Term:	Accidental ingestion may cause effects similar to those seen in clinical use. May cause hypersensitivity reactions in susceptible individuals.
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on liver, gastrointestinal system, and lymphatic system.
Known Clinical Effects:	Adverse effects most commonly reported in clinical use include skin reaction, skin rash, itching sensation (pruritus), diarrhea, nausea, fatigue, and immune-mediated disorders.
EU Indication of danger:	Not classified

Material Name: CP-675,206 IV Solution, 5mg/mL Revision date: 05-Apr-2007

Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
4. FIRST AID MEASURES	
Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
5. FIRE FIGHTING MEASURES	8
Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Formation of toxic gases is possible during heating or fire.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Fine particles (such as mists) may fuel fires/explosions.
6. ACCIDENTAL RELEASE MI	EASURES
Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Material Name: CP-675,206 IV Solution, 5mg/mL Revision date: 05-Apr-2007

General Handling:	Avoid open handling. Minimize generation of mists. Use local exhaust or perform work under hood/fume cupboard. Avoid inhalation and contact with skin, eyes, and clothing. When handling, use appropriate personal protective equipment (see Section 8).
Storage Conditions:	Store in a refrigerator. Do not freeze.
Storage Temperature:	2-8°C (36-46°F)

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

ACETIC ACID

OSHA - Final PELS - TWAs:	= 10 ppm TWA = 25 mg/m ³ TWA
ACGIH Threshold Limit Value	(TWA) = 10 ppm TWA
ACGIH Threshold Limit Value	(STEL) = 15 ppm STEL
Australia STEL	= 15 ppm STEL = 37 mg/m ³ STEL
Australia TWA	= 10 ppm TWA = 25 mg/m ³ TWA
Engineering Controls:	Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands:	Wear impervious gloves if skin contact is possible.
Eyes:	Safety glasses or goggles
Skin:	Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:	Liquid	Color:	Clear
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REA	СТІVІТҮ
Stability:	Stable under normal conditions of use.
Conditions to Avoid:	Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers.
11. TOXICOLOGICAL INF	ORMATION
General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Acute Toxicity: (Species, Rout	<u>e, End Point, Dose)</u>

Polysorbate 80

Rat Intravenous LD 50 1790 mg/kg

Material Name: CP-675,206 IV Solution, 5mg/mL Revision date: 05-Apr-2007 Page 4 of 6 Version: 2.1

Mouse Oral LD 50 25 g/kg

Sodium Acetate

Rat Oral LD 50 3500 mg/kg Mouse Oral LD 50 4960 mg/kg

SODIUM CHLORIDE

RatInhalationLC50/1hr> 42 g/m³RatOralLD 503 g/kgMouseOralLD 504 g/kgRabbitDermalLD 50> 10 g/kg

ACETIC ACID

MouseInhalationLC 505620 ppm/1HRatOralLD 503310 mg/kgRabbitDermalLD 501060 uL/kg

CP-675,206

 Non-human Primate
 IV
 Maximally Tolerated Dose 100 mg/kg

 Acute Toxicity Comments:
 A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

CP-675,206						
6 Month(s)	Monkey	Intravenous	15 mg/kg/week	. Maxim	ally Tolerated Dose	Skin, Blood, Gastrointestinal System,
Lymphatic sy	rstem					
1 Month(s)	Monkey	Intravenous	5 mg/kg/day	NOAEL	Blood, Gastrointesti	nal system, Liver, Lymphatic system

Carcinogen Status:

Not listed as a carcinogen by IARC, NTP or US OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties of the formulation have not been thoroughly investigated. Releases
	to the environment should be avoided.

Ingredients:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

ACETIC ACID

Fathead MinnowNPDESLC-5096 Hours88 mg/LBluegill SunfishNPDESLC-5096 Hours75 mg/LGoldfishNPDESLC-5024 Hours423 mg/L

Material Name: CP-675,206 IV Solution, 5mg/mL Revision date: 05-Apr-2007

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger:

Not classified

OSHA Label: WARNING May cause gastrointestinal system, liver, and blood effects.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Polysorbate 80	
Inventory - United States TSCA - Sect. 8(b)	XU
Australia (AICS):	Present
Sodium Acetate	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	204-823-8
	204-025-0
Water	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	231-791-2
SODIUM CHLORIDE	D
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	231-598-3
ACETIC ACID	
CERCLA/SARA Hazardous Substances	= 2270 kg final RQ
and their Reportable Quantities:	= 5000 lb final RQ
Inventory - United States TSCA - Sect. 8(b)	Present

Material Name: CP-675,206 IV Solution, 5mg/mL Revision date: 05-Apr-2007 Page 6 of 6 Version: 2.1

Australia (AICS): Standard for the Uniform Scheduling for Drugs and Poisons:		Present Schedule 2 Schedule 5 Schedule 6
EU EINECS List		200-580-7
16. OTHER INFORMATION	<u>1</u>	
Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 3 - Hazard Identification. Updated Section 11 - Toxicology Information.	
Prepared by:	Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety	

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet